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The most common molecular genetic change in prostate cancer involves silencing the expression of GSTP1, a critical enzyme of carcinogen defence. This change appears to occur early in prostate carcinogenesis, as it is found in virtually all cases of high-grade prostatic intraepithelial neoplasia, and is a near universal ®nding in clinical prostate cancers, regardless of grade or stage.
Abundant evidence suggests that the upregulation of the enzymes of carcinogen defence (phase 2 enzymes), including GSTP1, can protect against carcinogenesis in a variety of animal models. Indeed, several dietary micronutrients associated with protection against several human cancers are known to act through induction of phase 2 enzymes. Since prostate cancer is characterized by a phase 2 enzyme de®ciency, namely loss of GSTP1, we hypothesize that a rational prostate cancer prevention strategy may involved therapeutic biomodulation of phase 2 enzyme activity.
Method
We assessed over 50 candidate carcinogen detoxi®cation enzyme inducer compounds for their ability to induce increased quinone reductase (QR) activity in vitro in the human prostate cancer cell lines LNCaPazaC and LNCaP cells, which make and do not make GSTP1, respectively, and in human liver cells (HepG2). The screening strategy involved quantitative detection of QR activity after exposing prostate cancer cell lines to inducing agents. QR is induced co-ordinately with other phase 2 enzymes and remains stably expressed in cell culture.
Results
Striking differences in inducibility of QR were observed between the prostate and liver cell lines. Sulforaphane emerged as one of the most potent phase 2 enzymeinducing compounds in the prostate cancer cell lines. Induction of QR enzymatic activity with sulforaphane at nanomolar concentrations was observed in several prostate cancer cell lines and appears to be transcriptionally mediated. QR enzymatic activity increased two-to threefold over the DMSO-treated control cells 48 h after treatment with sulforaphane. Transcriptional induction of QR was measurable within 4 h of treatment and peaked by 8 h at levels three-to four-fold above control, and returned to baseline levels by 12 h. Despite this short duration of transcriptional induction, elevations of QR enzymatic activity persisted for up to 5 days following treatment. Sulforaphane treatment also increased mRNA expression of glutathione synthetic enzymes (gammaglutamylcysteine synthetase), glutathione S-transferase-a and microsomal glutathione transferase. This increased transcription was accompanied by induction of global GST enzymatic activity by 1.5-fold over control, as measured by the reduction of CDNB.
Conclusion
We are now evaluating the effects of sulforaphane on gene expression with cDNA micro-arrays encompassing some 10 000 human genes and ESTs. Preliminary work con®rms elevated expression of QR and glutathione transferases following treatment with sulforaphane, suggesting that it may affect other cellular pathways by modulating gene expression. Induction of phase 2 enzymatic activity with sulforaphane may offer a new, mechanistically based approach to primary prevention of prostate cancer. Measuring induction of carcinogen defence enzymes could serve as an intermediate endpoint biomarker for assessing the ef®cacy of such a preventive approach in clinical trials.
